RT @drdavidliew: TCZ in GCA: one disadvantage is that you can't use CRP+/- ESR for flares Mavrilimumab in GCA: - CRP/ES

TCZ in GCA: one disadvantage is that you can't use CRP+/- ESR for flares Mavrilimumab in GCA: - CRP/ESR consistently go up with symptomatic flares - CRP/ESR up less (cf. placebo), in the absence of Sx flares More signal, less noise. phase 2 post-hoc #ACR21 ABST1401 @RheumNow https://t.co/c0lMJMcQv0